THE LIPOSOME COMPANY SEES FDA APPROVAL OF ABLC FOR ASPERGILLOSIS FAILURES IN 1996; COMPANY RAISES $25 MIL. IN SECONDARY OFFERING TO PROTECT INDEPENDENCE
Executive Summary
The Liposome Company plans to file an NDA in 1995 for its ABLC amphotericin B lipid complex for use in aspergillosis patients who have failed conventional amphotericin B therapy, the company told the New York Society of Securities Analysts April 26 in New York City.